Introducing Dr. Hae Lim Lee Dr. Hae Lim Lee is a highly qualified clinical expert specializing in the treatment of liver diseases, including hepatitis, liver cancer, and liver transplants. She completed her Bachelor's degree in Medicine from Ewha Womans University in 2008, followed by a Master's degree in Internal Medicine from Catholic University in 2016. Currently, she is pursuing her Ph.D. in Internal Medicine at the Catholic University of Korea. Her extensive education has laid a strong foundation for her expertise in gastroenterology and hepatology. Dr. Lee has a wealth of experience in her field, having worked in various prestigious institutions. She is currently a Clinical Assistant Professor in the Department of Gastroenterology at Bucheon St. Mary's Hospital, where she has been serving since 2017. Previously, she held clinical instructor roles at both Bucheon St. Mary's Hospital and Seoul St. Mary's Hospital, where she was involved in educating the next generation of gastroenterology professionals. Her background in internal medicine and liver disease management has positioned her as a trusted expert in her field. At Bucheon St. Mary's Hospital, Dr. Lee leads the Organ Transplant Center, where she provides cutting-edge care to patients dealing with complex liver conditions. Her multidisciplinary approach ensures that each patient receives personalized and effective treatment for their specific needs. With a focus on liver transplant surgery and post-operative care, Dr. Lee works closely with her team to improve patient outcomes and quality of life. In addition to her clinical work, Dr. Lee is actively involved in the academic community, contributing to key organizations such as the Korean Liver Cancer Association and the Korean Association for the Study of the Liver. Her involvement in committees such as the Public Relations Committee and the Korean Liver Disease White Paper Revision Committee reflects her dedication to advancing the field of liver care. Dr. Lee's passion for research and education ensures that she remains at the forefront of liver disease treatment.